Novavax, a clinical-stage biopharmaceutical company focused on the development of recombinant nanoparticle vaccines and adjuvants, has promoted two members of its management team.
John Herrmann has been named Senior Vice President, General Counsel and Corporate Secretary. He joined Novavax in March 2010 and is responsible for managing all of Novavax's legal affairs, including its patent portfolio, transactional and contractual matters, public securities filings, and attending to all the duties of Corporate Secretary. Herrmann also works with the company's senior management team to define and develop corporate policies and procedures.
Prior to joining Novavax, Herrmann was General Counsel at Ore Pharmaceuticals and Deputy General Counsel at Gene Logic before it became Ore Pharmaceuticals. Before Gene Logic, he was Senior Counsel for Celera Genomics and prior to that Senior Corporate Counsel at Baxter Healthcare in its Renal Division.
In addition, Denise Courbron has been named Vice President, Global Programme Management to cover all vaccine development programmes.
Courbron joined Novavax in June 2010 as Executive Director, Global Programme Management and was instrumental in Novavax being awarded a US$179m influenza development contract with HHS BARDA in February 2011.
Prior to joining Novavax, she held positions of increasing responsibility in a number of companies in the vaccines industry, including PharmAthene, Intercell USA, Iomai Corporation, PPD, Baxter BioScience, GloboMax (ICON), and North American Vaccine.